Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids

  • S. Tobudic
  • W. Poeppl
  • C. Kratzer
  • A. Vychytil
  • H. BurgmannEmail author


Peritoneal dialysis used in the treatment of patients with end-stage renal failure is often complicated by peritonitis. Staphylococcus aureus peritonitis is severe, particularly if caused by a methicillin-resistant strain (MRSA). Intraperitoneal administration of drugs for treatment of peritonitis is preferable to intravenous or oral routes because of the resulting higher local antibiotic concentrations. However, peritoneal dialysis fluids (PDFs) have a bacteriostatic effect, which may compromise the efficacy of antibiotics. The bactericidal efficacy of vancomycin, teicoplanin, daptomycin and ceftobiprole was studied in the PDFs Dianeal PD4® (glucose 1.36%), Physioneal 40® (glucose 1.36%), Extraneal® (7.5% icodextrin), and Nutrineal PD4® (1.1% amino acid) using time-kill curves. To simulate in vivo conditions, human serum albumin was added at a final concentration of 2 g/l. All four PDFs had a bacteriostatic effect on the growth of the MRSA test isolate. All antibiotics showed less activity in PDFs compared to control broth. Vancomycin and teicoplanin achieved the greatest reduction in bacterial numbers in the amino-acid containing PDF Nutrineal PD4®. Daptomycin showed its highest activity in Extraneal® and better overall efficacy than the other tested antibiotics. Ceftobiprole showed no killing activities in any of the four PDFs. Based on these in vitro data we conclude that the choice of PDFs for intraperitoneal administration is not trivial and could be crucial for therapy outcome.


Vancomycin Peritonitis Peritoneal Dialysis Glycopeptide Teicoplanin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by internal funding.

Transparency declarations

None to declare.


  1. 1.
    Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L (2005) Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25(2):107–131PubMedGoogle Scholar
  2. 2.
    Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R, Rosales M, Villaverde P, Valdes F (2005) Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 25(3):274–284PubMedGoogle Scholar
  3. 3.
    Fried L, Abidi S, Bernardini J, Johnston JR, Piraino B (1999) Hospitalization in peritoneal dialysis patients. Am J Kidney Dis 33(5):927–933PubMedCrossRefGoogle Scholar
  4. 4.
    Fried LF, Bernardini J, Johnston JR, Piraino B (1996) Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 7(10):2176–2182PubMedGoogle Scholar
  5. 5.
    Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ (2002) Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 39(6):1278–1286PubMedCrossRefGoogle Scholar
  6. 6.
    Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W, Schaefer F, Struijk DG (2010) Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 30(4):393–423PubMedCrossRefGoogle Scholar
  7. 7.
    Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A (1986) Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob Agents Chemother 29(5):797–802PubMedGoogle Scholar
  8. 8.
    Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A (1986) The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132(5):1297–1304PubMedGoogle Scholar
  9. 9.
    Clouse FL, Hovde LB, Rotschafer JC (2007) In vitro evaluation of the activities of telavancin, cefazolin, and vancomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus in peritoneal dialysate. Antimicrob Agents Chemother 51(12):4521–4524PubMedCrossRefGoogle Scholar
  10. 10.
    Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC (2003) Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 47(12):3764–3767PubMedCrossRefGoogle Scholar
  11. 11.
    Clinical Laboratory Standards Institute C (2008) Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18. Wayne, PA, USAGoogle Scholar
  12. 12.
    Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, Harding G (2000) Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36(5):1009–1013PubMedCrossRefGoogle Scholar
  13. 13.
    Xu G, Tu W, Xu C (2010) Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 25(2):587–592PubMedCrossRefGoogle Scholar
  14. 14.
    de Vin F, Rutherford P, Faict D (2009) Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 29(1):5–15PubMedGoogle Scholar
  15. 15.
    McDonald WA, Watts J, Bowmer MI (1986) Factors affecting Staphylococcus epidermidis growth in peritoneal dialysis solutions. J Clin Microbiol 24(1):104–107PubMedGoogle Scholar
  16. 16.
    Schwartz MA, Buckwalter FH (1962) Pharmaceutics of penicillin. J Pharm Sci 51:1119–1128PubMedCrossRefGoogle Scholar
  17. 17.
    Mascio CT, Alder JD, Silverman JA (2007) Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51(12):4255–4260PubMedCrossRefGoogle Scholar
  18. 18.
    Carpenter CF, Chambers HF (2004) Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38(7):994–1000PubMedCrossRefGoogle Scholar
  19. 19.
    Salzer W (2005) Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 25(4):313–319PubMedGoogle Scholar
  20. 20.
    Wiggins KJ, Johnson DW, Craig JC, Strippoli GF (2007) Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. Am J Kidney Dis 50(6):967–988PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • S. Tobudic
    • 1
  • W. Poeppl
    • 1
  • C. Kratzer
    • 1
  • A. Vychytil
    • 2
  • H. Burgmann
    • 1
    Email author
  1. 1.Department of Internal Medicine I, Division of Infectious Diseases and Tropical MedicineMedical University of ViennaViennaAustria
  2. 2.Department of Internal Medicine III, Division of Nephrology and DialysisMedical University of ViennaViennaAustria

Personalised recommendations